In the MRL/lpr mouse model of SLE, exosome treatment reduced CD86 and increased CD206 expression in renal macrophages, along with lowered levels of pro-inflammatory cytokines (IFN-γ, IL-1β, IL-6) and elevated levels of anti-inflammatory cytokines (IL-10, TGF-β). The gene discussed is IL1B; the disease is systemic lupus erythematosus.